ARKG is trading 3.1% higher at $50.82, with no clear healthcare-sector catalyst identified; modest gains in major U.S. indexes are consistent with broader risk appetite returning after recent losses.
- The fund is concentrated in genomics and biotech names, including 10x Genomics, Twist Bioscience and Tempus AI.
- Pfizer’s TUKYSA approval is not an established driver, and the supplied context does not identify which holdings account for today’s gain.